Navigation Links
ICGC Releases New Genomic Data on Cancer Ahead of Schedule

TORONTO, July 11, 2011 /PRNewswire/ -- The International Cancer Genome Consortium (ICGC) today announced its sixth major data release at a meeting in Kyoto, Japan. The ICGC also announced that it is ahead of schedule in its decade-long goal to generate high-quality genomic data on more than 25,000 tumors for up to 50 types of cancer that are of clinical and societal importance across the globe.

"These new and updated datasets will help researchers better understand what drives cancer, which in turn should help develop new insights into how to tackle this terrible disease. Ultimately, this will lead to new, more personalized treatments that will improve patient care," said Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research and one of the founders of the ICGC. "As a result, these datasets are an important contribution not just to the ICGC but to the cancer research community worldwide."

The ICGC, comprised of research organizations around the world, is committed to making data rapidly and freely available. Cancer genome data is available on more than 2,800 tumors through an Internet portal at

The data include new submissions to the ICGC from The Cancer Genome Atlas (TCGA) in the United States, which has contributed information on about 10 types of cancer affecting the blood, brain, colon, kidney, lung, ovaries, rectum, and uterus, including data from a study of 500 ovarian cancer patients published in the journal Nature on June 30.

The National Cancer Center/RIKEN in Japan has updated its whole genome data on 27 liver cancers, which includes the first whole genome sequence data of HCV-positive HCC published in Nature Genetics on April 17. Researchers from Spain have provided complete genome sequences for patients with chronic lymphocytic leukemia (CLL). The Spanish team described recurrent mutations in CLL in a publication in Nature on June 5. The Ontario Institute for Cancer Research in Canada has updated its data on pancreatic cancer. The ICGC data portal also includes information on breast, lung, and skin cancer provided by researchers from the Wellcome Trust Sanger Institute in the United Kingdom.

More than 140 ICGC researchers are meeting at the first ICGC Workshop to be held in Asia. From July 10 to 12, the researchers meeting in Kyoto will discuss what has been discovered so far and to develop strategies for the future direction of the Consortium. Dr. Harold Varmus, Nobel laureate, is presenting a plenary lecture at this Workshop.  

"The relationship between the United States' TCGA initiative and the ICGC project is synergistic and will make major progress toward understanding the genetic underpinnings of more than 30 types of human cancer," said Harold Varmus, M.D., Director of the U.S. National Cancer Institute.  "An international commitment, both financially and intellectually, to an understanding of how human cancers occur across different populations will mean important progress for global health."

Although some projects targeting specific forms of cancer are already at the data generation stage, many of the 40 active projects are in their initial stages and are focused on obtaining patient consent and collecting 500 or more tumors of a specific form of cancer. The Consortium has proven to be very effective in generating guidelines and sharing knowledge to accelerate both existing and new projects in meeting their objectives.

The ICGC, which was formally launched in November 2008, continues to grow and attract new member projects. There currently are 40 projects underway targeting the bladder, blood, bone, brain, breast, cervix, colon, head and neck, kidney, liver, lung, oral cavity, ovary, pancreas, prostate, rectum, skin, soft tissues, stomach, and uterus.

Current ICGC funding member organizations include:Australia

National Health & Medical Research Council; Cancer Council New South Wales; Garvan Institute of Medical Research; Queensland State Government; Institute for Molecular Bioscience, University of QueenslandCanada

Canada Foundation for Innovation; Genome Canada; Ontario Institute for Cancer Research; Ontario Ministry of Research and Innovation; Prostate Cancer CanadaChina

Chinese Cancer Genome Consortium; Ministry of Science and Technology; National High Technology Research and Development Program ("863" Program) of China; Hong Kong University of Science & Technology (Observer Status)European Union

European Commission France

Institut National du Cancer (INCa) Germany

Federal Ministry of Education and Research (BMBF); German Cancer Aid (DKT) India

Department of Biotechnology, Ministry of Science & TechnologyItaly

Italian Ministry of Education University and Research; University of VeronaJapan

National Cancer Center; National Institute of Biomedical Innovation; RIKENMexico

Instituto Carlos Slim de la Salud Spain

Institute of Health Carlos III; Spanish Ministry of Science and Innovation United Kingdom

Bone Cancer Research Trust; Breakthrough Breast Cancer; Cancer Research UK; EuroBoNeT; Kay Kendall Leukaemia Fund; Skeletal Cancer Action Trust (Scat); The Wellcome Trust; Wellcome Trust Sanger InstituteUSA

National Cancer Institute; National Human Genome Research Institute; National Institutes of HealthThe ICGC enables free, rapid access to data. Data are available through the ICGC Data Coordination Centre housed in Toronto, Canada and through ICGC data portals in the Barcelona Supercomputing Center in Spain and the Queensland Centre for Medical Genomics in Australia.

For more information and updates about ICGC activities, please visit the website at:

For more information, please contact:

Michael J. Miller
Senior Science Writer
NCI Office of Media Relations
Telephone: (301) 402-6153

Rhea Cohen
Director of Communications
Ontario Institute for Cancer Research
Telephone: 416-673-6642
Mobile: 416-671-2846

Carolyn Norrie
National Health & Medical Research Council
Telephone:  +61 2 6217 9190

Tatsuhiro Shibata
Division of Cancer Genomics
Center for Medical Genomics
National Cancer Center Research Institute
Telephone: +81-3-3542-2511
Fax: +81-3-3547-5137

Hidewaki Nakagawa
Laboratory Head
Laboratory for Biomarker Development
Center for Genomic Medicine, RIKEN
Telephone: +81-3-5449-5785
Fax: +81-3-5449-5785

Global Relations Office
Telephone: +81-48-462-1225
Fax: +81-48-463-3687

National Cancer Center
Public Relations
Telephone: +81-3-3542-2511
Fax: +81-3-3542-2545

National Institute of Biomedical Innovation
Department of Research and Development Promotion
Research Promotion Section
Telephone: +81-72-641-9803
Fax: +81-72-641-9831

Daniel Mediavilla
Oficina de Prensa
Secretaria de Estado de Investigacion, Ministerio de Ciencia e Innovacion
Telephone: +34 659 995 973

United Kingdom
Mark Thomson
Press Officer
The Wellcome Trust Sanger Institute
Telephone: +44 (0) 1223 492385

SOURCE Ontario Institute for Cancer Research
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ACTE Releases Paper on How Career, Technical Student Organizations Expand Career Readiness for Students
2. HCCS Releases Classroom Management Features for Low Cost Learning Management System
3. Bayer CropScience Releases Video About Making Science Make Sense Program At Durham Performance Learning Center
4. MedeAnalytics Releases Analysis of Public Comments on ACO Proposed Rule
5. Unprecedented international meeting releases preliminary vision for our energy future
6. ClearCanvas Releases First Commercial Version of Widely Used PACS; Integrated RIS/PACS to Follow
7. Announcement - Clontech Laboratories, Inc. Releases the iDimerize™ Cell Signaling and Expression Systems
8. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
9. BioLegend Releases Brilliant Violet 421™ Antibody Conjugates For Advanced Flow Cytometry Applications.
10. ACO Proposed Rule Simplified: MedeAnalytics Releases Comprehensive White Paper
11. Clontech Laboratories, Inc. Releases the SMARTer™ Ultra Low RNA Kit for Illumina® Sequencing
Post Your Comments:
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):